LIFE SCIENCES & HEALTHCARE

CLIENT ALERT

DECEMBER/2019

ANVISA'S NEW REGULATION OF PRODUCTS CONTAINING *CANNABIS*

On December 3, 2019 the National Health Surveillance Agency (ANVISA) approved the Collegiate Board of Officers Resolution which regulates the manufacture, prescription, import and commercialization of products containing *Cannabis sativa* and sets forth the rules for monitoring and surveillance of products containing referred active ingredient for medicinal purposes.

Products containing cannabis will only be allowed for sale upon presentation of a special medical prescription which must be retained by the pharmacy or drugstore.

The regulation will be reviewed within 3 years.

The approved regulation will be published in the Official Gazette within the next days and will become in force after a 90-day *vacatio legis* period.

Veirano's **Life Sciences & Healthcare** team is at your attention to provide further information on this matter.

PRACTICE AREA
Life Sciences & Healthcare

COORDINATION
Lior Pinsky
Renata Fialho de Oliveira

For further information, please send a message to **news@veirano.com.br**

This document was prepared exclusively for informational purposes and does not constitute legal advice or an invitation to an attorney-client relationship. If you have any questions, our lawyers are available for clarification.

The reproduction or publication of this content is permitted, as long as followed by this copyright notice:
© Veirano Advogados.

© 2019 Veirano Advogados.
All rights reserved.